Weekly Update

Weekly Update: November 29 to December 03, 2021. The website analysis and mapping will be updated every two weeks starting December 2021.

New Studies with results available

5 new RCTs with results are available on our website: see here for vaccine et here for treatment

Dengiz E, Med Gas Res, 2022 Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial.
Dorward J, medrxiv, 2021 Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Ibarra-Estrada MA, Crit Care Med, 2021 Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure Due to Coronavirus Disease 2019: Results of a Single-Center Randomized Controlled Trial.
Parikh D, medrxiv, 2021 Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial
Somersan-Karakaya S, medrxiv, 2021 REGEN-COV for the Treatment of Hospitalized Patients with Covid-19

8 new or updated vaccine observational studies with results are available on our website: see here

Chadeau-Hyam M, medRxiv, 2021 REACT-1 study round 14: High and increasing prevalence of SARS-CoV-2 infection among school-aged children during September 2021 and vaccine effectiveness against infection in England
DE GIER B, MEDRXIV, 2021 COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021
Lin D, medRxiv, 2021 Effectiveness of Covid-19 Vaccines in the United States Over 9 Months: Surveillance Data from the State of North Carolina
LIU C, MEDRXIV, 2021 A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections – Risk Factors and Vaccine Effectiveness
Nordstrom P, SSRN, 2021 Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study
Polinski J, medRxiv, 2021 Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine
Singh C, Epidemiology and infection, 2021 Effectiveness of COVID-19 Vaccine in Preventing Infection and Disease Severity: A Case Control Study from an Eastern State of India
SKOWRONSKI DM, MEDRXIV, 2021 Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada

Studies pending data extraction

31 new pharmacological and/or preventive RCTs:

Absalon-Aguilar A, J Gen Intern Med, 2021 NCT04367168 Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID).
Arruda E A G, medrxiv, 2021 Clinical Trial of Efficacy and Toxicity of Disoproxil Tenofovir Fumarate and Emtricitabine for Mild to Moderate SARS-CoV-2 Infections
Asadi M, Diabetes Metab Syndr, 2021 Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial.
Asgardoon M, ResearchSquare, 2021 Efficacy of Levamisole with Standard Care Treatment vs Standard Care in Clinical Presentations of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial
Babalola O, ResearchSquare, 2021 A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria
Bar KJ, J Clin Invest, 2021 A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Davoodi L, Int J Cardiol Heart Vasc, 2021 Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial.
Faramarzi H, medrxiv, 2021 Efficacy and safety of a novel antiviral preparation in ICU-admitted patients with COVID-19: a phase III randomized controlled trial
Fralick M, medrxiv, 2021 Prone positioning of patients with moderate hypoxia due to COVID-19: A multicenter pragmatic randomized trial
Haeberle H, medrxiv, 2021 Inhaled Prostacyclin Improves Oxygenation in Patients with COVID-19-induced Acute Respiratory Distress Syndrome
Holubar M, medrxiv, 2021 Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
Huang L, medrxiv, 2021 Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial
Isa F, medrxiv, 2021 Repeat Subcutaneous Administration of REGEN-COV(R) in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19
Johansson PI, Am J Respir Crit Care Med, 2021 Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial
Jordan S, Unpublished, 2021 Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
Marcos M, Thromb Haemost, 2021 Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial.
Mazeraud A, Lancet Respir. Med., 2021 Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial
Menichetti F , JAMA, 2021 Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
Morici N, merdrxiv, 2021 Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. vs 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial
Nair PR, Respir Care, 2021 Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia.
Oliynyk O, Life, 2021 Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy.
Panda PK, Clin Pharmacol, 2021 Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19.
Ravishankar R, SSRN, 2021 Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Efficacy, Safety and Tolerability of Antiviral Drug Umifenovir vs Standard Care of Therapy in Non-Severe Covid-19 Patients
Roshon M, Infect Dis Ther, 2021 A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection.
Sarhan RM, J Infect Public Health, 2021 Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.
Seong S, ResearchSquare, 2021 A multicenter, randomized, double-blind, placebo-controlled phase ii trial of intravenous inflammasome inhibitor (NuSepin) for the treatment of COVID-19 patients
Shenoy S , medrxiv, 2021 Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.
Tornero C, medrxiv, 2021 Non-invasive Vagus Nerve Stimulation for Respiratory Symptoms of COVID-19: Results From a Randomized Controlled Trial (SAVIOR I)
Toroghi N, Pharmacol Rep, 2021 Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial
Zhuravel SV, EClinicalMedicine, 2021 Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial.

2 new vaccine RCTs:

Toledo-Romani ME, medrxiv, 2021(2) Safety and Immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme
Walter E, N Engl J Med, 2021 Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

We have identified additional COVID-19 RCTs assessing:

  1. long COVID
  2. other interventions (dietary supplements or minerals and other technologies (e.g. cytokine adsorption)
  3. other COVID vaccines.

These interventions were not prioritized but they might be included in the future. Details here